Surging Autoimmune Diseases Propel Growth In Interleukin Biosimilars Market Emerges as a Core Driver of the Biosimilar Interleukins Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Biosimilar Interleukins Market Through 2025?
The market size of biosimilar interleukins has witnessed exponential growth in the past few years. It is projected to expand from $3.9 billion in 2024 to $5.41 billion in 2025, marking a compound annual growth rate (CAGR) of 39.0%. Factors contributing to this remarkable growth during the historical period include heightened incidence of autoimmune diseases, growing awareness about biosimilar interleukins, increased government backing for biosimilars, the broadening scope of the biosimilar market, and heightened demand for biosimilars among patients.

What's the Projected Size of the Global Biosimilar Interleukins Market by 2029?
Predictions suggest a robust expansion for the biosimilar interleukins market in the coming years, with an estimated rise to $20.79 billion by 2029, presenting a compound annual growth rate (CAGR) of 40.0%. The projected growth during this period is a reflection of factors like the expanding patient base, broader healthcare access, rising interest in personalized medicine, and an upward trend in minimally invasive procedures. The forecast period is also likely to witness pivotal developments in the realm of biosimilar technology, targeted immunotherapies, quality control and manufacturing sectors, allied with enhanced global collaboration.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

Top Growth Drivers in the Biosimilar Interleukins Industry: What's Accelerating the Market?
The rise in autoimmune diseases like psoriasis and rheumatoid arthritis is anticipated to enhance the expansion of the interleukin biosimilars market in the projected timeline. Autoimmune disorders are situations where immune cells fail to differentiate between healthy cells and potentially harmful antibodies. Biopharmaceuticals such as anti-interleukin antibodies have demonstrated substantial clinical benefits in controlling the cells, guiding their proliferation, activation, and migration. For example, reports released by the National Institutes of Health (NIH), a biomedical research institution in the US, in February 2024, indicate that the annual global increases in incidence and prevalence of autoimmune diseases are estimated at 19.1% and 12.5% respectively. Hence, the escalating occurrence of autoimmune diseases is amplifying the demand for the biosimilar interleukins market, which is likely to propel the market growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

What Trends Will Shape the Biosimilar Interleukins Market Through 2029 and Beyond?
Key players in the biosimilar interleukins market are advancing their market position through the innovation of new offerings, such as Tofidence (tocilizumab-bavi). This product is a monoclonal antibody designed to attach to interleukin-6 receptors and has found use in treating a range of inflammatory autoimmune diseases. For example, in September 2023, Tofidence secured FDA approval as the inaugural biosimilar product referencing Genentech's Actemra (tocilizumab); this assertion comes following a successful application by the US biotech firm, Biogen. Administered via an intravenous infusion, Tofidence has been approved for use in the treatment of severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

What Are the Main Segments in the Biosimilar Interleukins Market?
The biosimilar interleukins market covered in this report is segmented -

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3433&type=smp

Which Top Companies are Driving Growth in the Biosimilar Interleukins Market?
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

Which Regions Will Dominate the Biosimilar Interleukins Market Through 2029?
The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3433

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.